A Multiplexed Lateral Flow Assay for The Serologic Point of Care Detection of HPV Positive Cervical Cancer

Human Papillomavirus (HPV) is the most commonly transmitted STI and isresponsible for an estimated 5% of cancer cases worldwide. HPV infection is implicated in 70% of cervical cancer incidence and is also responsible for a variety of oropharyngeal and anogenital cancers. While vaccination has greatly reduced the cervical cancer burden in developed countries, HPV infection remains high in developing countries due to high cost and poor access to healthcare. Several studies have highlighted the presence of anti-HPV antibodies following infection and their potential use as biomarkers for developing novel screening methods. Progression from initial infection to cancer is slow, thus presenting an opportunity for effective screening programs. Biomarker screening is an important area of cancer detection and Lateral Flow Assays (LFA) are a low cost, easy to use alternative to other screening methods that require extensive training and laboratory space. Therefore, this project proposes as a hypothesis that the development of an LFA screening for HPV specific IgG can provide clinically relevant data for the early detection of cervical dysplasia. This project adapts an LFA in a multiplexed format for fluorescence-based serologic detection of HPV specific IgG in patient plasma.